Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/69913
Campo DC Valoridioma
dc.contributor.authorLloret Sáez-Bravo, Martaen_US
dc.contributor.authorGarcía-Cabrera, L.en_US
dc.contributor.authorHernandez, A.en_US
dc.contributor.authorSantana, N.en_US
dc.contributor.authorLópez-Molina, L.en_US
dc.contributor.authorLara Jiménez, Pedro Carlosen_US
dc.date.accessioned2020-02-05T12:51:14Z-
dc.date.available2020-02-05T12:51:14Z-
dc.date.issued2019en_US
dc.identifier.issn1699-048Xen_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/69913-
dc.description.abstractBackground: Hyperthermia (HT) is used to increase the temperature of the tumor-sensitizing cells to the effects of radiation/chemotherapy. We aimed to assess the feasibility, tolerability and safety of hyperthermia treatment in a Radiation Oncology Department. Methods: Between June 2015 and June 2017, 106 patients and a total of 159 tumor lesions were included in a prospective study (EudraCT 2018-001089-40) of HT concomitant with radiotherapy (RT). Systemic treatment was accepted. HT was given twice a week, 60 min per session, during RT treatment by a regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. Results: Most lesions (138 cases, 86.8%) received all HT sessions planned. Thirteen lesions (12 patients) withdrew treatment due to grade ≥3 QMHT toxicity. All these 12 patients completed the prescribed radiotherapy and/or systemic treatment. Conclusions: Regional hyperthermia is a feasible and safe technique to be used in combination with radiotherapy and systemic treatment.en_US
dc.languageengen_US
dc.relation.ispartofClinical and Translational Oncologyen_US
dc.sourceClinical and Translational Oncology [ISSN 1699-048X], v. 21 (12), p. 1771-1775en_US
dc.subject320101 Oncologíaen_US
dc.subject.otherAdvanced Tumorsen_US
dc.subject.otherHyperthermiaen_US
dc.subject.otherRadiotherapyen_US
dc.titleFeasibility of a deep hyperthermia and radiotherapy programme for advanced tumors: first Spanish experienceen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s12094-019-02097-9en_US
dc.identifier.scopus85066013648-
dc.identifier.isi000495304300018-
dc.contributor.authorscopusid7003855087-
dc.contributor.authorscopusid56386004800-
dc.contributor.authorscopusid57209137760-
dc.contributor.authorscopusid57208888768-
dc.contributor.authorscopusid57208880435-
dc.contributor.authorscopusid7004374085-
dc.description.lastpage1775en_US
dc.identifier.issue12-
dc.description.firstpage1771en_US
dc.relation.volume21en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid21486072-
dc.contributor.daisngid12394394-
dc.contributor.daisngid24938106-
dc.contributor.daisngid24615672-
dc.contributor.daisngid4788905-
dc.contributor.daisngid591076-
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Lloret, M-
dc.contributor.wosstandardWOS:Garcia-Cabrera, L-
dc.contributor.wosstandardWOS:Hernandez, A-
dc.contributor.wosstandardWOS:Santana, N-
dc.contributor.wosstandardWOS:Lopez-Molina, L-
dc.contributor.wosstandardWOS:Lara, PC-
dc.date.coverdateDiciembre 2019en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,833
dc.description.jcr2,737
dc.description.sjrqQ2
dc.description.jcrqQ3
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.fullNameLloret Sáez-Bravo, Marta-
crisitem.author.fullNameLara Jiménez, Pedro Carlos-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

3
actualizado el 21-abr-2024

Citas de WEB OF SCIENCETM
Citations

3
actualizado el 25-feb-2024

Visitas

101
actualizado el 09-mar-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.